Vis børsmeldingen
Photocure expects product revenue growth in the range of 7% to 11% and year-over
-year EBITDA improvement in 2025. While the company is not providing a specific
EBITDA guidance range, Photocure expects continued operating leverage flow
-through in its core commercial business and significant growth in milestones
this year.
“We delivered strong performance in the fourth quarter of 2024 with 13% growth
in Hexvix/Cysview revenue, 11% unit sales growth, and EBITDA of NOK 8.5 million.
For the full-year 2024, we grew product revenue by 10% and generated EBITDA of
NOK 49.2 million. We continue to execute on growing our Hexvix/Cysview business
and have consistently produced positive EBITDA over the last 7 quarters,” says
Dan Schneider, President & Chief Executive Officer of Photocure.
Photocure reported total group revenues of NOK 141.7 million in the fourth
quarter of 2024 (NOK 142.5 million), and EBITDA* of NOK 8.5 million (Q4 2023:
NOK 29.9 million), while Hexvix/Cysview revenues grew to NOK 128.6 million in
the quarter (NOK 114.2 million). The EBIT was NOK 1.2 million (NOK 22.5 million)
and the cash balance at the end of the period was NOK 293.8 million (NOK 259.5
million).
At the end of the fourth quarter of 2024, the installed base of rigid blue light
cystoscopy (BLC®) systems in the U.S. was 390, up 11% since the same period in
2023. This includes 18 ForTec Medical mobile towers. Photocure estimates that 25
flexible BLC towers remain in the U.S. market.
During the quarter, Olympus launched its high-definition blue light cystoscopy
upgrade for its state-of-the-art Viscera Elite III endoscopic platform, which
Photocure believes will increase the use of Hexvix in certain Nordic countries
and elsewhere in Europe. Also, subsequently in February, Photocure provided an
update from its collaboration with Richard Wolf disclosing that a flexible BLC
interim solution is now available in Europe.
“We remain focused on the growth of our business and investing in opportunities
that can take Photocure to the next level in 2025. Supporting our expected
growth this year, our U.S. business is performing well as we continue to
increase the base of active accounts using BLC, and mobile tower adoption is
anticipated to outweigh remaining declines in flexible BLC usage. New
therapeutics entering the market to treat NMIBC** are expected to continue
raising the awareness of precision bladder cancer management and emphasizing the
importance of better detection with BLC and Hexvix/Cysview. Additionally, the
launch of Olympus’ upgraded BLC equipment in Europe is now underway, and our
partnership with Richard Wolf is progressing well with a flexible BLC interim
solution available sooner than expected,” Schneider adds.
Photocure believes that the benefits of Blue Light Cystoscopy with
Hexvix/Cysview offering superior detection and management of bladder cancer will
continue to be adopted and become the standard of care. Photocure expects
product revenue growth in the range of 7% to 11% and YoY EBITDA improvement in
2025. While the Company is not providing a specific EBITDA guidance range,
Photocure expects continued operating leverage flow-through in its core
commercial business and significant growth in milestones this year.
“We reported our strongest revenue ever in Q4 2024, and our full year revenue
and EBITDA results demonstrate Photocure’s ability to execute through headwinds,
generate growth and create significant opportunities for the Company,” Schneider
concludes.
Please find the full financial report and presentation enclosed.
EBITDA* and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
fourth quarter 2024 financial report on page 23.
The quarterly report and presentation will be published at 08:00 CEST and will
be publicly available at www.photocure.com. Dan Schneider, CEO and Erik Dahl,
CFO, will host a live webcast at 14:00 CET.
The presentation will be held in English and questions can be submitted
throughout the event. The streaming event is available through
https://channel.royalcast.com/landingpage/hegnarmedia/20250219_4/
The presentation is scheduled to conclude at 14:45 CET.
NMIBC**: Non muscle-invasive bladder cancer
For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no
David Moskowitz
Vice President of Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com/news.
All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act. This stock exchange
announcement was published by Tolv Hillestad, Group Controller, Photocure ASA,
on 19 February 2025 at 08:00 CET.
Kilde
